Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo.

ABSTRACT:

Background

Mycobacterium abscessus causes chronic pulmonary infections. Owing to its resistance to most classes of antibiotics, treatment is complex and cure rates are only 45%. Tigecycline is active against M. abscessus, but severe toxicity and the need for IV administration limit its use.

Objectives

To assess the potential of inhaled tigecycline as a treatment for M. abscessus pulmonary disease, by measuring its efficacy in a mouse model of chronic M. abscessus pulmonary disease, establishing the intracellular activity of tigecycline against M. abscessus in human macrophages and measuring the activity of tigecycline in the sputum of cystic fibrosis patients.

Methods

We infected GM-CSF knockout mice with M. abscessus by intrapulmonary aerosol. Infected mice were trea

SUBMITTER: Pearce C 

PROVIDER: S-EPMC7778363 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature